10 [78] S. R. Datta, A. Brunet, and M. E. Greenberg, “Cellular survival: a play in three akts,” Genes and Development, vol. 13, no. 22, pp. 2905–2927, 1999. [79] A. Dickey, S. Schleicher, K. Leahy, R. Hu, D. Hallahan, and D. K. Thotala, “GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line,” Journal of Neuro-Oncology, vol. 104, pp. 145–153, 2010. [80] G. P. Meares and R. S. Jope, “Resolution of the nuclear local- ization mechanism of glycogen synthase kinase-3: functional eﬀects in apoptosis,” Journal of Biological Chemistry, vol. 282, no. 23, pp. 16989–17001, 2007. [81] S. Korur, R. M. Huber, B. Sivasankaran et al., “GSK3beta regulates diﬀerentiation and growth arrest in glioblastoma,” PloS One, vol. 4, no. 10, article e7443, 2009. [82] S. Kotliarova, S. Pastorino, L. C. Kovell et al., “Glycogen syn- thase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-κB, and glucose regulation,” Cancer Research, vol. 68, no. 16, pp. 6643–6651, 2008. [83] M. Sun, L. Song, Y. Li, T. Zhou, and R. S. Jope, “Identiﬁcation of an antiapoptotic protein complex at death receptors,” Cell Death and Diﬀerentiation, vol. 15, no. 12, pp. 1887–1900, 2008. [84] R. Vene`, P. Larghero, G. Arena, M. B. Sporn, A. Albini, and F. Tosetti, “Glycogen synthase kinase 3β regulates cell death induced by synthetic triterpenoids,” Cancer Research, vol. 68, no. 17, pp. 6987–6996, 2008. [85] A. Damalas, A. Ben-Ze’ev, I. Simcha et al., “Excess β- catenin promotes accumulation of transcriptionally active p53,” EMBO Journal, vol. 18, no. 11, pp. 3054–3063, 1999. [86] E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze’ev, “Down- regulation of β-catenin by activated p53,” Molecular and Cellular Biology, vol. 21, no. 20, pp. 6768–6781, 2001. [87] G. P. Meares, M. A. Mines, E. Beurel et al., “Glycogen syn- thase kinase-3 regulates endoplasmic reticulum (ER) stress- induced CHOP expression in neuronal cells,” Experimental Cell Research, vol. 317, no. 11, pp. 1621–1628, 2011. [88] K. P. Hoeﬂich, J. Luo, E. A. Rubie, M. S. Tsao, O. Jin, and J. R. Woodgett, “Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation,” Nature, vol. 406, no. 6791, pp. 86–90, 2000. [89] F. Demarchi, C. Bertoli, P. Sandy, and C. Schneider, “Glyco- gen synthase kinase-3β regulates NF-κB1/p105 stability,” Journal of Biological Chemistry, vol. 278, no. 41, pp. 39583– 39590, 2003. [90] R. F. Schwabe and D. A. Brenner, “Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes,” American Journal of Physiology, vol. 283, no. 1, pp. G204–G211, 2002. [91] J. Deng, S. A. Miller, H. Y. Wang et al., “β-catenin interacts with and inhibits NF-κB in human colon and breast cancer,” Cancer Cell, vol. 2, no. 4, pp. 323–334, 2002. [92] F. Gotschel, C. Kern, S. Lang et al., “Inhibition of GSK3 diﬀerentially modulates NF-kappaB, CREB, AP-1 and beta- catenin signaling in hepatocytes, but fails to promote TNF- alpha-induced apoptosis,” Experimental Cell Research, vol. 314, no. 6, pp. 1351–1366, 2008. [93] P. Schotte, G. Van Loo, I. Carpentier, P. Vandenabeele, and R. Beyaert, “Lithium sensitizes tumor cells in an NFκB- independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF): evidence for a role of the TNF receptor-associated death domain protein,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 25939–25945, 2001. International Journal of Cell Biology [94] X. Liao, L. Zhang, J. B. Thrasher, J. Du, and B. Li, “Glycogen synthase kinase-3beta suppression eliminates tumor necro- sis factor-related apoptosis-inducing ligand resistance in prostate cancer.,” Molecular Cancer Therapeutics, vol. 2, no. 11, pp. 1215–1222, 2003. [95] G. N. Bijur and R. S. Jope, “Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β,” Jour- nal of Biological Chemistry, vol. 276, no. 40, pp. 37436–37442, 2001. [96] F. Takahashi-Yanaga and T. Sasaguri, “GSK-3β regulates cyclin D1 expression: a new target for chemotherapy,” Cellular Signalling, vol. 20, no. 4, pp. 581–589, 2008. [97] A. Arcaro and M. P. Wymann, “Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses,” Biochemical Journal, vol. 296, no. 2, pp. 297–301, 1993. [98] M. Pap and G. M. Cooper, “Role of glycogen synthase kinase- 3 in the phosphatidylinositol 3- kinase/Akt cell survival pathway,” Journal of Biological Chemistry, vol. 273, no. 32, pp. 19929–19932, 1998. [99] C. J. Vlahos, W. F. Matter, K. Y. Hui, and R. F. Brown, “A speciﬁc inhibitor of phosphatidylinositol 3- kinase, 2-(4-morpholinyl)- 8-phenyl-4H-1-benzopyran-4- one (LY294002),” Journal of Biological Chemistry, vol. 269, no. 7, pp. 5241–5248, 1994. [100] S. Arico, S. Pattingre, C. Bauvy et al., “Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent pro- tein kinase-1 activity in the human colon cancer HT-29 cell line,” Journal of Biological Chemistry, vol. 277, no. 31, pp. 27613–27621, 2002. [101] M. M. Hill, M. Andjelkovic, D. P. Brazil, S. Ferrari, D. Fabbro, and B. A. Hemmings, “Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 25643–25646, 2001. [102] A. R. Hussain, M. Al-Rasheed, P. S. Manogaran et al., “Cur- cumin induces apoptosis via inhibition of PI3 -kinase/AKT pathway in acute T cell leukemias,” Apoptosis, vol. 11, no. 2, pp. 245–254, 2006. [103] F. Meggio, A. Donella Deana, M. Ruzzene et al., “Diﬀerent susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2,” European Journal of Biochemistry, vol. 234, no. 1, pp. 317–322, 1995. [104] A. Noe¨l, L. Barrier, F. Rinaldi, C. Hubert, B. Fauconneau, and S. Ingrand, “Lithium chloride and staurosporine poten- tiate the accumulation of phosphorylated glycogen synthase kinase 3β/Tyr216, resulting in glycogen synthase kinase 3β activation in SH-SY5Y human neuroblastoma cell lines,” Journal of Neuroscience Research, vol. 89, no. 5, pp. 755–763, 2011. [105] J. P. Alao, A. V. Stavropoulou, E. W. F. Lam, and R. C. Coombes, “Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic eﬀects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells,” Molecular Cancer, vol. 5, article 40, 2006. [106] L. Yang, H. C. Dan, M. Sun et al., “Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt,” Cancer Research, vol. 64, no. 13, pp. 4394–4399, 2004. [107] J. Dong, J. Peng, H. Zhang et al., “Role of glycogen synthase kinase 3β in rapamycin-mediated cell cycle regulation and